U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C22H25N3O3
Molecular Weight 379.4522
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SPIROXATRINE

SMILES

O=C1NCN(C2=CC=CC=C2)C13CCN(CC4COC5=C(O4)C=CC=C5)CC3

InChI

InChIKey=JVGBTTIJPBFLTE-UHFFFAOYSA-N
InChI=1S/C22H25N3O3/c26-21-22(25(16-23-21)17-6-2-1-3-7-17)10-12-24(13-11-22)14-18-15-27-19-8-4-5-9-20(19)28-18/h1-9,18H,10-16H2,(H,23,26)

HIDE SMILES / InChI

Description

Spiroxatrine is a drug which acts as a selective antagonist at both the 5-HT1A receptor and the α2 adrenergic receptor. Spiroxatrine was identified as a moderately potent but non-selective agonist at the human nociceptin/orphanin FQ receptor, ORL1

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
2.5 nM [Kd]
1.45 nM [Ki]
149.0 nM [Ki]
118.0 nM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
Single injection - 1 mg/kg
Route of Administration: Intraperitoneal
In Vitro Use Guide
Using whole cells in suspension, the cell surface receptors were preincubated for 1h in 96-wells microtiter plates with a high (19xKi) concentration of an antagonist (Spiroxatrine) in order to obtain 95% saturation of antagonist binding to the receptors. The assay volume was 150 μl. Then, the microtiter plates were centrifuged at 3000 rpm (1110g) for 3min.This attached the HEK293 cells with antagonist-blocked receptors to the bottom surface. The microplate was then centrifuged upside-down at 600 rpm (44g) for 10 s to remove the liquid and unbound ligand while retaining cells, including bound ligand, attached to the bottom surface. Immediately, 300 μl of binding buffer (including about 2 nM [3H]-RX821002) was added rather forcefully to the cells. Thereby, most of the HEK293 cells became re-suspended, due to that cell attachment was weak since attachment of the cells had been achieved just by the previous centrifugation in the calcium-free buffer. This step also defines T0 in the on-reaction for the radioligand as well as T0 in the off-reaction for the antagonist. Thereafter, the assays were filtered at different time points. The first filtration was performed after the 30s, then after 2, 6, 15, 36 and 72 min.